Tropical Medicine & Surgery is an open access publication that features scientific works of considerable significance and impact in all aspects of Tropical Medicine and Surgery: Emerging Infectious Diseases, Neglected Tropical Diseases, Non communicable Diseases, Tropical Biomedicine, Tropical Diseases, Tropical Fish Diseases, Tropical Fish Medicine, Tropical Health Nutrition, Tropical Medicine, Tropical Medicine and Health and Tropical Medicine and Hygiene.

In July 2022, the World Health Organization deemed the monkeypox outbreak a public health emergency of global concern. The COVID-19 Dermatology Registry was subsequently enlarged by the American Academy of Dermatology and International League of Dermatological Societies to form the "AAD/ILDS Dermatology COVID-19, Monkeypox, and Emerging Infections Registry". The registry's objective is to quickly compile instances of monkeypox and other emerging illnesses, allowing for quick distribution of information to front-line healthcare providers and other members of the medical community. Reports of cases of monkeypox and skin reactions to the monkeypox/smallpox vaccine are now being accepted by the registry. The international dermatology community's active case entry will be crucial to the success of this collaborative effort.

The epidemic of monkeypox around the globe was deemed a public health emergency of international concern by the World Health Organization on July 23, 2022.

Two weeks later, the "AAD/ILDS Dermatology COVID-19, Monkeypox, and Emerging Infections Registry" was launched by the American Academy of Dermatology (AAD) and International League of Dermatological Societies (ILDS) as an addition to the COVID-19 Dermatology Registry platform. The expanded registry, which was established on August 4, 2022—the same day the United States declared monkeypox a public health emergency—accepts cases of monkeypox and reactions to the monkeypox/smallpox vaccine in order to improve understanding of the disease's clinical presentation, course, and treatment outcomes globally.

The AAD/ILDS registry was first created with the intention of quickly compiling instances of COVID-19 dermatologic symptoms and enabling immediate distribution of findings to front-line healthcare professionals. The dermatology community has been able to assist in the public health understanding of COVID-19 infection and combat false information about vaccine reactions thanks to information from the registry, which has resulted in 20 publications, data sharing across multiple platforms/countries, and more than 190 million media impressions. These COVID-19-related cases, as well as any future instances of monkeypox, reactions to the monkeypox vaccine, and newly emerging diseases, will all be included to the registry.

Due to the fact that cases are not meant to replace reliable epidemiologic data, data gathering with registries has various limitations.

The goal of this endeavour is not to publish disease incidence, but rather to enable the larger medical community to quickly communicate observations about how diseases present and manifest themselves, and to act as a tool for developing hypotheses.

The transmission of reliable statistics will become even more important as reports of disproportionate effects on vulnerable communities, such as those with concurrent STIs (29%), persons living with HIV (35% to 42%), and groups within the LGBTQ community, continue to increase.

The ability of the medical community to recognise cases will be essential for containment if treatment or prophylaxis are not widely available.